Evidence map›Paper›PMID 26550574›Full record

ArticleBioMed research international2015

The diagnosis value of promoter methylation of UCHL1 in the serum for progression of gastric cancer.

Gongping Wang, Wei Zhang, Bo Zhou, Canhui Jin, Zengfang Wang, Yantong Yang, Zhenzhen Wang, Ye Chen, Xiaoshan Feng

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. PMEnvironmental health and preventive medicine · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. PositiveOncotarget · 2017
    Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gongping WangDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Wei ZhangDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Bo ZhouDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Canhui JinDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Zengfang WangDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Yantong YangDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Zhenzhen WangDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Ye ChenDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
Xiaoshan FengDepartment of Gastrointestinal Oncology Surgery, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471003, China.
First Affiliated Hospital of Henan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAberrant promoter methylation has been considered as a potential molecular marker for gastric cancer (GC). However, the role of methylation of FLNC, THBS1, and UCHL1 in the development and progression of GC has not been explored.

methodsThe promoter methylation status of UCHL1, FLNC, THBS1, and DLEC1 was assessed by quantitative methylation-specific PCR (QMSP) in the serum of 82 GC patients, 46 chronic atrophic gastritis (CAG) subjects, and 40 healthy controls.

resultsAll four genes had significantly higher methylation levels in GC patients than in CAG and control subjects. However, only UCHL1 methylation was significantly correlated with the tumor stage and lymph node metastasis. While THBS1 methylation was altered in an age-dependent manner, FLNC methylation was correlated with differentiation and Helicobacter pylori infection. DLEC1 methylation was only associated with tumor size. Moreover, methylated UCHL1 with or without THBS1 in the serum was found to be significantly associated with a poor prognosis.

conclusionThe promoter methylation degree of FLNC, THBS1, UCHL1, and DLEC1 in serum could tell the existence of GC and only UCHL1 in the serum was also associated with poor prognosis of GC.

Indexed as

AgedBiomarkers, TumorChinaDisease ProgressionDNA MethylationFemaleGenetic MarkersGenetic Predisposition to DiseaseHumansMaleMiddle AgedNeoplasm StagingPrevalencePromoter Regions, GeneticReproducibility of ResultsRisk FactorsBiomarkers, TumorGenetic MarkersUbiquitin ThiolesteraseUCHL1 protein, human

Identifiers

PMID26550574
PMCPMC4624918
OpenAlexW2101139431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.